Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Key Inclusion Criteria: * Able to provide written informed consent and commit to EAP assessments. * ≥18 years of age. * Able to swallow tablets. * Diagnosed with ASM, SM-AHN, MCL, BMM, ISM, or SSM according to the 2022 WHO Classification for SM * Not receiving adequate disease control on current therapy(ies). * Have clinically acceptable laboratory screening results. Exclusion Criteria: * Patients who are eligible for and/or enrolled in an on-going bezuclastinib clinical trial. * Patients who discontinued investigational use of bezuclastinib in previous clinical trials due to toxicity or withdrawal of consent. * Pregnant or currently breastfeeding. * Prior or ongoing clinically significant illness or medical or physical condition Other protocol-defined criteria apply.